Together we are beating cancer

Donate now

Prostate cancer

Around 47,700 men are diagnosed with prostate cancer in the UK each year, making it the most common cancer in men in the UK. It develops in the prostate, a walnut-sized gland found at the base of the bladder.
Showing 12 out of 226 results
The logo of our podcast, That Cancer Conversation

In this episode of That Cancer Conversation, we're going to take you into the world of clinical research and walk you through the pathway to give you the full picture of what a clinical trial really involves.  In this episode of That Cancer Conversation, we're going to take you into the world of clinical research and walk you through the pathway to give you the full picture of what a clinical trial really involves. 

by Cancer Research UK | Podcast | 27 November 2023

27 November 2023

This entry is part 12 of 14 in the series That Cancer Conversation
Breast cancer cells

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

by Tim Gunn | News | 11 April 2023

11 April 2023

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022

Photograph of a person having an MRI scan.

New research has found that using an advanced MRI technique may enable doctors to pinpoint potentially aggressive or fast-growing cancers and guide treatment pathways. New research has found that using an advanced MRI technique may enable doctors to pinpoint potentially aggressive or fast-growing cancers and guide treatment pathways.

by Lilly Matson | Analysis | 14 February 2022

14 February 2022

prostate cancer biopsy
  • Health & Medicine
  • Science & Technology

Targeted prostate cancer screening: Are we there yet?

Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet? Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?

by Katie Roberts | Analysis | 20 October 2021

20 October 2021

Prostate cancer cells
  • Science & Technology
  • Health & Medicine

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference. Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

by Cancer Research UK | News | 19 September 2021

19 September 2021

A microscopy image showing ball of prostate cells expressing a potential new marker (red) for aggressive prostate cancer.

Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option. Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option.

by Cancer Research UK | News | 14 September 2021

14 September 2021

Lung adenocarcinoma cells
  • Science & Technology
  • Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

by Harry Jenkins | Analysis | 9 June 2021

9 June 2021